Nerve Agent Articles & Analysis
8 news found
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving surgical precision in the operating room, has announced the start of participation in a clinical trial combining its fluorescence-guided surgery (FGS) imaging device with a novel nerve-targeting agent. OnLume has unique FGS imaging technology to illuminate critical anatomy in real time during ...
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). This grant will support Alume's clinical development of its novel nerve illumination technology in surgery. The Principal Investigators on this ...
[BROOMFIELD, CO – 31 MARCH 2020] Shortly after receiving a $24.5 million project from the Department of Defense (DOD) to develop a scopolamine auto-injector, Aktiv Pharma Group has been awarded a $16 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for ...
[BROOMFIELD, MARCH 23, 2020] Aktiv Pharma Group has been awarded a $24.5 million US government project to develop an autoinjector treatment for exposure to nerve agents. The award is an Other Transaction (OT) prototype project by the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEOCBRND). Under the 5-year, OT agreement, ...
Crossject and the US Department of Defense - DOD - (who is in charge of chemical, biological, radiological and nuclear defense – JPM CBRN Medical) have signed a cooperative research and development agreement for Zeneo® Midazolam. « We are really happy to have signed this cooperative research and development agreement with the US Department of Defense (DOD), after their audit when ...